BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25032734)

  • 1. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
    Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
    Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
    Inukai D; Nishimura K; Okamoto H; Sano R; Ueda H; Ota A; Karnan S; Hosokawa Y; Yoshikawa K; Suzuki S; Ueda R; Murotani K; Bradford CR; Ogawa T
    Nagoya J Med Sci; 2020 Aug; 82(3):519-531. PubMed ID: 33132436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
    Ijichi K; Adachi M; Ogawa T; Hasegawa Y; Murakami S
    Anticancer Res; 2014 Jun; 34(6):2907-11. PubMed ID: 24922653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
    Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
    Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
    Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma.
    Aoki K; Ogawa T; Ito Y; Nakashima S
    Oncol Rep; 2004 Feb; 11(2):375-9. PubMed ID: 14719071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
    Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
    Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
    Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
    Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
    Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
    Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
    Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing heat shock protein 27 decreases metastatic behavior of human head and neck squamous cell cancer cells in vitro.
    Zhu Z; Xu X; Yu Y; Graham M; Prince ME; Carey TE; Sun D
    Mol Pharm; 2010 Aug; 7(4):1283-90. PubMed ID: 20540527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.